Pub Date : 2024-10-31Epub Date: 2024-10-28DOI: 10.21037/tau-24-239
Fabian Steinkohl, Anna K Luger, Leonhard Gruber, Renate Pichler, Isabel Heidegger, Jasmin Bektic, Friedrich Aigner
Background: Prostate biopsies are an invasive procedure that can lead to anxieties and fear before the examination. Prostate magnetic resonance imaging (MRI) is seen as a non-invasive test although it is known that "scanxiety" affects many patients. Transrectal ultrasound (TRUS)-guided prostate biopsies and multiparametric prostate MRI (mpMRI) are commonly used methods in patients with suspected prostate cancer (PCa). This study investigates fears and anxieties towards the TRUS and mpMRI.
Methods: All patients scheduled for mpMRI or TRUS biopsy between January and December 2018 were asked to participate in this single-center study. A total of 196 completed questionnaires were returned and included.
Results: On a 5-point Likert scale the fear of the examination was lower for the mpMRI [1.53; 95% confidence interval (CI): 1.38 to 1.69] than for a TRUS biopsy (2.47; 95% CI: 2.21 to 2.71). In detail, patients with a scheduled TRUS biopsy had significantly higher levels for fear of pain [2.49 (95% CI: 2.19 to 2.78) vs. 1.51 (95% CI: 1.35 to 1.67); P<0.001] and fear of complications [2.71 (95% CI: 2.45 to 2.98) vs. 2.11 (95% CI: 1.89 to 2.32); P=0.001]. There was no relevant difference about the fact that patients knew what to expect [3.02 (95% CI: 2.68 to 3.35) vs. 2.99 (95% CI: 2.70 to 3.26); P=0.47] and the expectation that the examination will go over well [3.24 (95% CI: 2.92 to 3.57) vs. 3.27 (95% CI: 3.00 to 3.58); P=0.55].
Conclusions: On average, fear levels were moderate before mpMRI and TRUS biopsy. Patients are more afraid of TRUS biopsy than mpMRI but the differences were low. The biggest fear remains the fear of the result of the examinations independently of the method.
背景:前列腺活检是一项侵入性检查,可能导致患者在检查前产生焦虑和恐惧。前列腺磁共振成像(MRI)被视为非侵入性检查,但众所周知,"扫描焦虑症 "会影响许多患者。经直肠超声(TRUS)引导的前列腺活组织检查和多参数前列腺磁共振成像(mpMRI)是疑似前列腺癌(PCa)患者常用的检查方法。本研究调查了患者对 TRUS 和 mpMRI 的恐惧和焦虑:2018年1月至12月期间,所有计划接受mpMRI或TRUS活检的患者均被要求参与这项单中心研究。共收回并纳入196份填写完整的调查问卷:在5点Likert量表中,mpMRI检查的恐惧感[1.53;95%置信区间(CI):1.38至1.69]低于TRUS活检(2.47;95% CI:2.21至2.71)。具体而言,计划接受 TRUS 活检的患者对疼痛的恐惧程度明显更高[2.49 (95% CI: 2.19 to 2.78) vs. 1.51 (95% CI: 1.35 to 1.67);Pvs. 2.11 (95% CI: 1.89 to 2.32);P=0.001]。患者对检查结果的预期[3.02 (95% CI: 2.68 to 3.35) vs. 2.99 (95% CI: 2.70 to 3.26); P=0.47]和对检查结果的预期[3.24 (95% CI: 2.92 to 3.57) vs. 3.27 (95% CI: 3.00 to 3.58); P=0.55]没有相关差异:mpMRI和TRUS活检前的平均恐惧程度为中等。患者对 TRUS 活检的恐惧程度高于 mpMRI,但差异较小。最大的恐惧仍然是对检查结果的恐惧,与检查方法无关。
{"title":"Patients' anxieties and fears: a comparison between transrectal prostate biopsy and prostate MRI.","authors":"Fabian Steinkohl, Anna K Luger, Leonhard Gruber, Renate Pichler, Isabel Heidegger, Jasmin Bektic, Friedrich Aigner","doi":"10.21037/tau-24-239","DOIUrl":"10.21037/tau-24-239","url":null,"abstract":"<p><strong>Background: </strong>Prostate biopsies are an invasive procedure that can lead to anxieties and fear before the examination. Prostate magnetic resonance imaging (MRI) is seen as a non-invasive test although it is known that \"scanxiety\" affects many patients. Transrectal ultrasound (TRUS)-guided prostate biopsies and multiparametric prostate MRI (mpMRI) are commonly used methods in patients with suspected prostate cancer (PCa). This study investigates fears and anxieties towards the TRUS and mpMRI.</p><p><strong>Methods: </strong>All patients scheduled for mpMRI or TRUS biopsy between January and December 2018 were asked to participate in this single-center study. A total of 196 completed questionnaires were returned and included.</p><p><strong>Results: </strong>On a 5-point Likert scale the fear of the examination was lower for the mpMRI [1.53; 95% confidence interval (CI): 1.38 to 1.69] than for a TRUS biopsy (2.47; 95% CI: 2.21 to 2.71). In detail, patients with a scheduled TRUS biopsy had significantly higher levels for fear of pain [2.49 (95% CI: 2.19 to 2.78) <i>vs.</i> 1.51 (95% CI: 1.35 to 1.67); P<0.001] and fear of complications [2.71 (95% CI: 2.45 to 2.98) <i>vs.</i> 2.11 (95% CI: 1.89 to 2.32); P=0.001]. There was no relevant difference about the fact that patients knew what to expect [3.02 (95% CI: 2.68 to 3.35) <i>vs.</i> 2.99 (95% CI: 2.70 to 3.26); P=0.47] and the expectation that the examination will go over well [3.24 (95% CI: 2.92 to 3.57) <i>vs.</i> 3.27 (95% CI: 3.00 to 3.58); P=0.55].</p><p><strong>Conclusions: </strong>On average, fear levels were moderate before mpMRI and TRUS biopsy. Patients are more afraid of TRUS biopsy than mpMRI but the differences were low. The biggest fear remains the fear of the result of the examinations independently of the method.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 10","pages":"2201-2208"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31Epub Date: 2024-10-28DOI: 10.21037/tau-24-342
Ekamjit S Deol, Francis A Jefferson, Anthony E Fadel, Vidit Sharma, Daniel J Blezek, Daniel S Elliott, Boyd R Viers, Brian J Linder
Background: Sarcopenia, characterized by low muscle mass, and aberrant adiposity changes, including visceral fat accumulation, has been associated with impaired physiologic stress response and wound healing. Artificial urinary sphincter (AUS) placement is the preferred surgical treatment for men with severe post-prostatectomy incontinence. Given the higher rates of maladaptive body composition changes in this older, high comorbidity population, this study explores their impact on AUS outcomes.
Methods: A retrospective analysis was performed including men who underwent primary AUS placement at the Mayo Clinic from 1999 to 2023 for post-prostatectomy incontinence and had cross sectional imaging available within 12 months prior to AUS implant. Sarcopenia and body composition were assessed from the available computed tomography (CT) scan using an algorithm that measures the area of different tissues at the L3 abdominal cross-section. The study investigated the association between sarcopenia [defined as skeletal muscle index (SMI) <52.4 cm2/m2] and adiposity (defined by total visceral and subcutaneous fat area) with all-cause reoperation, including specific etiologies of device infection/erosion, urethral atrophy, and device malfunction, using Cox proportional hazards models.
Results: There were 111 patients who had available imaging within the study timeframe, 61 (55%) of whom were classified as sarcopenic. Follow-up did not differ significantly between the two groups [2.11 (0.53-4.78) vs. 2.52 (0.36-5.80) years, P=0.52]. Sarcopenic patients had a lower body mass index (BMI) (29.1 vs. 32.7 kg/m2; P<0.001). No significant difference in overall device survival was observed between sarcopenic and non-sarcopenic patients (P=0.94) on Cox survival analysis. Sarcopenic patients had higher device infection rates, accounting for 16.7% (3/18) of device failures in the sarcopenic cohort compared to none in the non-sarcopenic cohort.
Conclusions: Sarcopenia was prevalent among AUS patients but did not significantly impact overall device survival. These findings suggest that AUS placement may be feasible to perform in well-selected sarcopenic patients.
背景:肌肉疏松症的特点是肌肉质量低、脂肪异常变化(包括内脏脂肪堆积),与生理应激反应和伤口愈合受损有关。人工尿道括约肌(AUS)置入术是前列腺切除术后严重尿失禁男性的首选手术治疗方法。考虑到这一高龄、高合并症人群的身体成分不良变化率较高,本研究探讨了这些变化对人工尿道括约肌置入术结果的影响:本研究进行了一项回顾性分析,研究对象包括1999年至2023年期间因前列腺切除术后尿失禁而在梅奥诊所接受初级AUS置入术的男性,他们在AUS植入前12个月内接受了横断面影像学检查。根据现有的计算机断层扫描(CT)扫描结果,采用测量 L3 腹部横截面不同组织面积的算法,对肌肉疏松症和身体成分进行了评估。研究采用 Cox 比例危险模型,调查了肌肉疏松症(定义为骨骼肌指数 (SMI) 2/m2)和肥胖症(定义为内脏和皮下脂肪总面积)与全因再手术之间的关系,包括器械感染/侵蚀、尿道萎缩和器械故障等特定病因:共有 111 名患者在研究时间范围内进行了影像学检查,其中 61 人(55%)被归类为肌无力患者。两组患者的随访时间差异不大[2.11(0.53-4.78)年 vs. 2.52(0.36-5.80)年,P=0.52]。肌少症患者的体重指数(BMI)较低(29.1 vs. 32.7 kg/m2;PC结论:肌肉疏松症在 AUS 患者中很普遍,但对设备的总体存活率没有明显影响。这些研究结果表明,在精心挑选的肌肉疏松患者中进行 AUS 置入手术是可行的。
{"title":"Evaluating the impact of artificial intelligence-based assessment of body composition on primary artificial urinary sphincter placement outcomes.","authors":"Ekamjit S Deol, Francis A Jefferson, Anthony E Fadel, Vidit Sharma, Daniel J Blezek, Daniel S Elliott, Boyd R Viers, Brian J Linder","doi":"10.21037/tau-24-342","DOIUrl":"10.21037/tau-24-342","url":null,"abstract":"<p><strong>Background: </strong>Sarcopenia, characterized by low muscle mass, and aberrant adiposity changes, including visceral fat accumulation, has been associated with impaired physiologic stress response and wound healing. Artificial urinary sphincter (AUS) placement is the preferred surgical treatment for men with severe post-prostatectomy incontinence. Given the higher rates of maladaptive body composition changes in this older, high comorbidity population, this study explores their impact on AUS outcomes.</p><p><strong>Methods: </strong>A retrospective analysis was performed including men who underwent primary AUS placement at the Mayo Clinic from 1999 to 2023 for post-prostatectomy incontinence and had cross sectional imaging available within 12 months prior to AUS implant. Sarcopenia and body composition were assessed from the available computed tomography (CT) scan using an algorithm that measures the area of different tissues at the L3 abdominal cross-section. The study investigated the association between sarcopenia [defined as skeletal muscle index (SMI) <52.4 cm<sup>2</sup>/m<sup>2</sup>] and adiposity (defined by total visceral and subcutaneous fat area) with all-cause reoperation, including specific etiologies of device infection/erosion, urethral atrophy, and device malfunction, using Cox proportional hazards models.</p><p><strong>Results: </strong>There were 111 patients who had available imaging within the study timeframe, 61 (55%) of whom were classified as sarcopenic. Follow-up did not differ significantly between the two groups [2.11 (0.53-4.78) <i>vs.</i> 2.52 (0.36-5.80) years, P=0.52]. Sarcopenic patients had a lower body mass index (BMI) (29.1 <i>vs.</i> 32.7 kg/m<sup>2</sup>; P<0.001). No significant difference in overall device survival was observed between sarcopenic and non-sarcopenic patients (P=0.94) on Cox survival analysis. Sarcopenic patients had higher device infection rates, accounting for 16.7% (3/18) of device failures in the sarcopenic cohort compared to none in the non-sarcopenic cohort.</p><p><strong>Conclusions: </strong>Sarcopenia was prevalent among AUS patients but did not significantly impact overall device survival. These findings suggest that AUS placement may be feasible to perform in well-selected sarcopenic patients.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 10","pages":"2238-2245"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31Epub Date: 2024-10-28DOI: 10.21037/tau-24-350
Anthony Fadel, Boyd R Viers, J Nick Warner, Katherine T Anderson
Background: Adult acquired buried penis (ABP) is a heterogenous condition and surgical treatment typically includes several steps. Additionally, there is no consensus on which current procedural terminology (CPT) codes to utilize for these steps. Our objective is to characterize the variability in CPT codes reported for ABP surgeries. We hypothesize that the heterogeneous disease process combined with a lack of consensus on appropriate CPT codes will result in marked variability in CPT codes reported during surgery for ABP.
Methods: Data was collected from American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) between 2007-2020. We included adults undergoing surgery for ABP. All CPT codes were grouped into different anatomic categories: penile procedures, scrotal procedures, pannus-related procedures, urethral procedures, tissue transfers, and skin grafts. Codes not fitting these categories were labeled "Other".
Results: Our study included 146 patients. There were 413 total CPT codes reported with 82 unique codes in our cohort. The average number of codes per patient was 2.8, with a range from 1 to 9. There were many unique codes in each anatomic category: 18 different codes within penile procedures, 7 within pannus procedures, 8 within skin grafting, 4 within scrotal procedures, 7 within tissue transfers, and 19 within urethral. There was marked variability in individual code use with each code being reported anywhere from 1 to 58 times. Urologists were the primary surgeons in 69% (n=101).
Conclusions: We found marked variability in CPT codes reported during surgery for ABP. This suggests the need for our stakeholder organizations to support efforts that would allow consensus on which codes should be utilized for this increasingly recognized condition.
{"title":"Acquired buried penis: an observational study characterizing the variability in procedural codes reported during surgery.","authors":"Anthony Fadel, Boyd R Viers, J Nick Warner, Katherine T Anderson","doi":"10.21037/tau-24-350","DOIUrl":"10.21037/tau-24-350","url":null,"abstract":"<p><strong>Background: </strong>Adult acquired buried penis (ABP) is a heterogenous condition and surgical treatment typically includes several steps. Additionally, there is no consensus on which current procedural terminology (CPT) codes to utilize for these steps. Our objective is to characterize the variability in CPT codes reported for ABP surgeries. We hypothesize that the heterogeneous disease process combined with a lack of consensus on appropriate CPT codes will result in marked variability in CPT codes reported during surgery for ABP.</p><p><strong>Methods: </strong>Data was collected from American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) between 2007-2020. We included adults undergoing surgery for ABP. All CPT codes were grouped into different anatomic categories: penile procedures, scrotal procedures, pannus-related procedures, urethral procedures, tissue transfers, and skin grafts. Codes not fitting these categories were labeled \"Other\".</p><p><strong>Results: </strong>Our study included 146 patients. There were 413 total CPT codes reported with 82 unique codes in our cohort. The average number of codes per patient was 2.8, with a range from 1 to 9. There were many unique codes in each anatomic category: 18 different codes within penile procedures, 7 within pannus procedures, 8 within skin grafting, 4 within scrotal procedures, 7 within tissue transfers, and 19 within urethral. There was marked variability in individual code use with each code being reported anywhere from 1 to 58 times. Urologists were the primary surgeons in 69% (n=101).</p><p><strong>Conclusions: </strong>We found marked variability in CPT codes reported during surgery for ABP. This suggests the need for our stakeholder organizations to support efforts that would allow consensus on which codes should be utilized for this increasingly recognized condition.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 10","pages":"2229-2237"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31Epub Date: 2024-10-28DOI: 10.21037/tau-24-274
Wenhui Wu, Xiaohong Guo, Jie Li, Min Yang, Yongai Xiong
Background: Allium tuberosum Rottler improves sexual function and is used in the treatment of impotence and spermatorrhea. However, its chemical composition and mechanism of action remain unclear. This study investigates the chemical composition and mechanism of action of Allium tuberosum Rottler co-processed with salt and wine (GZP) in modulating testicular mitochondrial autophagy for the treatment of asthenozoospermia in mice.
Methods: Adenine gavage + cyclophosphamide intraperitoneal injection was used to establish the model of asthenozoospermia, and six Allium tuberosum Rottler processed products were compared in the pharmacological efficacy for the treatment of asthenozoospermia in mice. The liquid chromatograph mass spectrometer (LC-MS) assay was performed to analyse the compositional changes in the GZP. The mechanism of GZP in the treatment of asthenozoospermia in mice was further investigated. The mitophagy was detected by transmission electron microscope (TEM) and immunofluorescence, respectively. Reactive oxygen species (ROS) were detected by probe. Protein expression was determined by Western blotting.
Results: GZP exhibited optimal therapeutic effects on asthenozoospermia in mice. It showed the best therapeutic effect in improving the total number of spermatozoa, sperm survival rate, improving sperm viability and reducing sperm deformity rate, alleviating the abnormal pathological morphology of mice testis, and increasing the serum testosterone (T), follicle-stimulating hormone (FSH) and prolactin (PRL) levels in mice. The LC-MS detection found that Allicin showed the most significant increase in GZP. Besides, GZP reduced ROS level and inhibited mitophagy in mice testicular tissues. Meanwhile, it restrained the expression of PINK1, Parkin, Light chain 3II (LC3-II)/Light chain 3I (LC3-I) and Caspase-3 proteins.
Conclusions: GZP improves asthenozoospermia via inhibiting excessive mitophagy and protects the integrity of mitochondria by blocking the PINK1/Parkin signaling pathway. During which, the Allicin may play an important role.
{"title":"Comparison of different processed products of <i>Allium tuberosum Rottler</i> for the treatment of mice asthenozoospermia.","authors":"Wenhui Wu, Xiaohong Guo, Jie Li, Min Yang, Yongai Xiong","doi":"10.21037/tau-24-274","DOIUrl":"10.21037/tau-24-274","url":null,"abstract":"<p><strong>Background: </strong><i>Allium tuberosum Rottler</i> improves sexual function and is used in the treatment of impotence and spermatorrhea. However, its chemical composition and mechanism of action remain unclear. This study investigates the chemical composition and mechanism of action of <i>Allium tuberosum Rottler</i> co-processed with salt and wine (GZP) in modulating testicular mitochondrial autophagy for the treatment of asthenozoospermia in mice.</p><p><strong>Methods: </strong>Adenine gavage + cyclophosphamide intraperitoneal injection was used to establish the model of asthenozoospermia, and six <i>Allium tuberosum Rottler</i> processed products were compared in the pharmacological efficacy for the treatment of asthenozoospermia in mice. The liquid chromatograph mass spectrometer (LC-MS) assay was performed to analyse the compositional changes in the GZP. The mechanism of GZP in the treatment of asthenozoospermia in mice was further investigated. The mitophagy was detected by transmission electron microscope (TEM) and immunofluorescence, respectively. Reactive oxygen species (ROS) were detected by probe. Protein expression was determined by Western blotting.</p><p><strong>Results: </strong>GZP exhibited optimal therapeutic effects on asthenozoospermia in mice. It showed the best therapeutic effect in improving the total number of spermatozoa, sperm survival rate, improving sperm viability and reducing sperm deformity rate, alleviating the abnormal pathological morphology of mice testis, and increasing the serum testosterone (T), follicle-stimulating hormone (FSH) and prolactin (PRL) levels in mice. The LC-MS detection found that Allicin showed the most significant increase in GZP. Besides, GZP reduced ROS level and inhibited mitophagy in mice testicular tissues. Meanwhile, it restrained the expression of PINK1, Parkin, Light chain 3II (LC3-II)/Light chain 3I (LC3-I) and Caspase-3 proteins.</p><p><strong>Conclusions: </strong>GZP improves asthenozoospermia via inhibiting excessive mitophagy and protects the integrity of mitochondria by blocking the PINK1/Parkin signaling pathway. During which, the Allicin may play an important role.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 10","pages":"2209-2228"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31Epub Date: 2024-10-28DOI: 10.21037/tau-24-338
Sue W Goldstein, Noel N Kim, Irwin Goldstein
<p><strong>Background: </strong>Electrohydraulic shockwave devices have been Food and Drug Administration-cleared for improved blood flow and connective tissue activation and have been used to treat erectile dysfunction (ED). In this study, the main focus was to evaluate improvement in erectile tissue quality after low intensity shockwave therapy (LiSWT).</p><p><strong>Methods: </strong>A single-blind, sham-controlled, randomized, prospective study, was performed in men with ED naïve to shockwave or radial ballistic pressure wave therapy. Participants were randomized 1:2 to simulated (sham) or active LiSWT treatment. After simulated treatments, participants in the Sham Arm were converted to active LiSWT, while participants initially in the Active Treatment Arm received no further treatment. Assessments were performed at baseline and two follow-up visits. Subjective parameters of erectile function (EF) were assessed by total and EF domain scores of the International Index of Erectile Function (IIEF) and sexual encounter profile (SEP). Objective parameters of penile erection were measurements of hypoechoic areas in images obtained by grayscale ultrasound (GUS) with high resolution 15.4 MHz probe and cavernosal artery peak systolic velocity (PSV) and end diastolic velocity (EDV) by color duplex Doppler ultrasound (DUS). Outcome measures for erectile and urinary function were also obtained.</p><p><strong>Results: </strong>Simulated LiSWT did not significantly change any assessment parameter. Sham Arm participants who converted to active LiSWT had significantly increased mean IIEF total (P=0.02) and IIEF-EF scores that approached statistical significance (P=0.06), relative to baseline. Similarly, at the end of the study, Active Treatment Arm participants had significantly increased mean IIEF total (P=0.02) and IIEF-EF scores that approached statistical significance (P=0.07), relative to baseline. Additionally, at the end of the study, SEP3 success rates (erection lasting long enough for successful intercourse) approached statistical significance when Sham Arm participants were converted to active LiSWT (P=0.08) and reached statistical significance in the Active Treatment Arm (P=0.049). GUS assessments by visual grading were significantly correlated to IIEF-EF score (P=0.002) and were significantly increased relative to baseline in the Active Treatment Arm at follow-up Assessment 1 (P=0.03) and Assessment 2 (P=0.04). The greatest reduction in hypoechoic area after LiSWT occurred in the proximal penile shaft. EDV was also significantly reduced in the Active Treatment Arm at follow-up Assessment 1 (P=0.04) and Assessment 2 (P=0.04). LiSWT also resulted in improved prostate symptom scores, approaching significance in the Active Treatment Arm (P=0.055) with no changes in prostate-specific antigen. Treatment-related adverse events were limited and transient.</p><p><strong>Conclusions: </strong>In this prospective trial, LiSWT was safe and efficacious for er
{"title":"Randomized trial of low intensity shockwave therapy for erectile dysfunction utilizing grayscale ultrasound for analysis of erectile tissue homogeneity/inhomogeneity.","authors":"Sue W Goldstein, Noel N Kim, Irwin Goldstein","doi":"10.21037/tau-24-338","DOIUrl":"10.21037/tau-24-338","url":null,"abstract":"<p><strong>Background: </strong>Electrohydraulic shockwave devices have been Food and Drug Administration-cleared for improved blood flow and connective tissue activation and have been used to treat erectile dysfunction (ED). In this study, the main focus was to evaluate improvement in erectile tissue quality after low intensity shockwave therapy (LiSWT).</p><p><strong>Methods: </strong>A single-blind, sham-controlled, randomized, prospective study, was performed in men with ED naïve to shockwave or radial ballistic pressure wave therapy. Participants were randomized 1:2 to simulated (sham) or active LiSWT treatment. After simulated treatments, participants in the Sham Arm were converted to active LiSWT, while participants initially in the Active Treatment Arm received no further treatment. Assessments were performed at baseline and two follow-up visits. Subjective parameters of erectile function (EF) were assessed by total and EF domain scores of the International Index of Erectile Function (IIEF) and sexual encounter profile (SEP). Objective parameters of penile erection were measurements of hypoechoic areas in images obtained by grayscale ultrasound (GUS) with high resolution 15.4 MHz probe and cavernosal artery peak systolic velocity (PSV) and end diastolic velocity (EDV) by color duplex Doppler ultrasound (DUS). Outcome measures for erectile and urinary function were also obtained.</p><p><strong>Results: </strong>Simulated LiSWT did not significantly change any assessment parameter. Sham Arm participants who converted to active LiSWT had significantly increased mean IIEF total (P=0.02) and IIEF-EF scores that approached statistical significance (P=0.06), relative to baseline. Similarly, at the end of the study, Active Treatment Arm participants had significantly increased mean IIEF total (P=0.02) and IIEF-EF scores that approached statistical significance (P=0.07), relative to baseline. Additionally, at the end of the study, SEP3 success rates (erection lasting long enough for successful intercourse) approached statistical significance when Sham Arm participants were converted to active LiSWT (P=0.08) and reached statistical significance in the Active Treatment Arm (P=0.049). GUS assessments by visual grading were significantly correlated to IIEF-EF score (P=0.002) and were significantly increased relative to baseline in the Active Treatment Arm at follow-up Assessment 1 (P=0.03) and Assessment 2 (P=0.04). The greatest reduction in hypoechoic area after LiSWT occurred in the proximal penile shaft. EDV was also significantly reduced in the Active Treatment Arm at follow-up Assessment 1 (P=0.04) and Assessment 2 (P=0.04). LiSWT also resulted in improved prostate symptom scores, approaching significance in the Active Treatment Arm (P=0.055) with no changes in prostate-specific antigen. Treatment-related adverse events were limited and transient.</p><p><strong>Conclusions: </strong>In this prospective trial, LiSWT was safe and efficacious for er","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 10","pages":"2246-2267"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31Epub Date: 2024-10-28DOI: 10.21037/tau-24-335
Silu Chen, Kunlin Yang, Zhenyu Li, Zhihua Li, Zihao Tao, Yiming Zhang, Xiang Wang, Xuesong Li
Buccal mucosal graft (BMG) ureteroplasty, particularly with the anterior-onlay technique, shows promise for treating complex ureteral strictures. However, long and circumferential strictures remain challenging. This study aimed to present the surgical technique of the posterior-inlay and anterior-onlay technique in robotic ureteroplasty with a BMG (RU-BMG). A 37-year-old male patient with a medical background of failed laparoscopic ureteroplasty and multiple endourological interventions was admitted to our hospital. Preoperative anterograde and retrograde pyelography revealed a 5-cm ureteral stricture. During the surgical procedure, the ureteral posterior wall was insufficient to facilitate a complete posterior augmented anastomosis, resulting in a posterior defect subsequent to the partial posterior augmented anastomosis. Ultimately, a BMG was utilized to address the posterior defect initially, followed by anterior-onlay ureteroplasty with a BMG. The Foley catheter was removed 2 weeks after surgery, while the nephrostomy tube was clamped on postoperative day 14. The double-J stent was removed 3 months after surgery. The preoperative serum creatine was 102.9 μmol/L. The surgery was performed successfully within 240 min, with estimated blood loss of 100 mL. The postoperative hospitalization was 4 days. Throughout the 12-month follow-up period, no symptoms or complications were observed, with a serum creatine of 82.0 μmol/L. Computed tomography urography indicated relieved hydronephrosis. In conclusion, RU-BMG using a combination of posterior-inlay and anterior-onlay technique is safe and feasible in the management of ureteral stricture. More cases and longer follow-up for this procedure are needed for better perfection of this procedure.
{"title":"Robotic buccal mucosal graft ureteroplasty using combination of posterior-inlay and anterior-onlay technique.","authors":"Silu Chen, Kunlin Yang, Zhenyu Li, Zhihua Li, Zihao Tao, Yiming Zhang, Xiang Wang, Xuesong Li","doi":"10.21037/tau-24-335","DOIUrl":"10.21037/tau-24-335","url":null,"abstract":"<p><p>Buccal mucosal graft (BMG) ureteroplasty, particularly with the anterior-onlay technique, shows promise for treating complex ureteral strictures. However, long and circumferential strictures remain challenging. This study aimed to present the surgical technique of the posterior-inlay and anterior-onlay technique in robotic ureteroplasty with a BMG (RU-BMG). A 37-year-old male patient with a medical background of failed laparoscopic ureteroplasty and multiple endourological interventions was admitted to our hospital. Preoperative anterograde and retrograde pyelography revealed a 5-cm ureteral stricture. During the surgical procedure, the ureteral posterior wall was insufficient to facilitate a complete posterior augmented anastomosis, resulting in a posterior defect subsequent to the partial posterior augmented anastomosis. Ultimately, a BMG was utilized to address the posterior defect initially, followed by anterior-onlay ureteroplasty with a BMG. The Foley catheter was removed 2 weeks after surgery, while the nephrostomy tube was clamped on postoperative day 14. The double-J stent was removed 3 months after surgery. The preoperative serum creatine was 102.9 μmol/L. The surgery was performed successfully within 240 min, with estimated blood loss of 100 mL. The postoperative hospitalization was 4 days. Throughout the 12-month follow-up period, no symptoms or complications were observed, with a serum creatine of 82.0 μmol/L. Computed tomography urography indicated relieved hydronephrosis. In conclusion, RU-BMG using a combination of posterior-inlay and anterior-onlay technique is safe and feasible in the management of ureteral stricture. More cases and longer follow-up for this procedure are needed for better perfection of this procedure.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 10","pages":"2330-2337"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31Epub Date: 2024-10-28DOI: 10.21037/tau-24-279
Ali Bourgi, Franck Bruyere, Hugo Crespin
Background: Artificial urinary sphincter (AUS) is the gold standard for severe male stress urinary incontinence (SUI). This study aims to evaluate the interest of a new cutaneous preparation regarding the risk of early device infection.
Methods: A retrospective review of medical records has been built with all patients who underwent an AUS, implanted by experienced surgeons, between January 2010 and January 2023. Before January 2015, all AUS received a standard protocol (SP) of cutaneous cleansing with soap povidone iodine and disinfection with alcoholic povidone iodine. After January 2015, all AUS received the new protocol (NP) with two cleansings with soap povidone iodine and two disinfections with alcoholic povidone iodine. The primary focus was to compare the risk of early device infection between the two protocols. Multivariate analyses were done with several risk factors such as age, diabetes, underlying pathology (prostate cancer surgery, surgical treatment of benign prostatic hyperplasia or others), past history of pelvic radiation therapy and past AUS implantation.
Results: One hundred and fifty-six cases were enrolled, with 34 following the SP and 122 following the NP. In the univariate analysis, there were 15 explantations in the SP arm versus 8 for the NP arm due to infection (45.5% vs. 25%, P=0.09). The was no difference between the NP and the SP in multiparametric analysis [odds ratio (OR): 0.97; P=0.96]. No other risk factors were associated with increased risk of AUS removal.
Conclusions: Our study showed no correlation between the two types of skin preparation and the risk of AUS removal or revision. Future studies are needed to highlight the legitimate risk factors.
背景:人工尿道括约肌(AUS)是治疗严重男性压力性尿失禁(SUI)的金标准。本研究旨在评估一种新型皮肤制剂对早期装置感染风险的影响:方法:对 2010 年 1 月至 2023 年 1 月期间由经验丰富的外科医生植入 AUS 的所有患者的病历进行回顾性审查。2015 年 1 月前,所有 AUS 都接受了用肥皂聚维酮碘清洗皮肤并用酒精聚维酮碘消毒的标准方案 (SP)。2015 年 1 月后,所有 AUS 都接受了新方案(NP),即用肥皂聚维酮碘清洗两次,用酒精聚维酮碘消毒两次。主要重点是比较两种方案的早期器械感染风险。对年龄、糖尿病、潜在病理(前列腺癌手术、良性前列腺增生手术治疗或其他)、既往盆腔放疗史和既往 AUS 植入史等风险因素进行了多变量分析:156 例病例中,34 例采用了 SP,122 例采用了 NP。在单变量分析中,SP植入组有15例因感染而切除,而NP植入组有8例(45.5%对25%,P=0.09)。在多参数分析中,NP和SP之间没有差异[几率比(OR):0.97;P=0.96]。没有其他风险因素与AUS切除风险的增加有关:我们的研究表明,两种备皮方式与AUS移除或翻修风险之间没有相关性。今后的研究需要强调合理的风险因素。
{"title":"Skin preparation before artificial urinary sphincter surgery: is there a difference between protocols?","authors":"Ali Bourgi, Franck Bruyere, Hugo Crespin","doi":"10.21037/tau-24-279","DOIUrl":"10.21037/tau-24-279","url":null,"abstract":"<p><strong>Background: </strong>Artificial urinary sphincter (AUS) is the gold standard for severe male stress urinary incontinence (SUI). This study aims to evaluate the interest of a new cutaneous preparation regarding the risk of early device infection.</p><p><strong>Methods: </strong>A retrospective review of medical records has been built with all patients who underwent an AUS, implanted by experienced surgeons, between January 2010 and January 2023. Before January 2015, all AUS received a standard protocol (SP) of cutaneous cleansing with soap povidone iodine and disinfection with alcoholic povidone iodine. After January 2015, all AUS received the new protocol (NP) with two cleansings with soap povidone iodine and two disinfections with alcoholic povidone iodine. The primary focus was to compare the risk of early device infection between the two protocols. Multivariate analyses were done with several risk factors such as age, diabetes, underlying pathology (prostate cancer surgery, surgical treatment of benign prostatic hyperplasia or others), past history of pelvic radiation therapy and past AUS implantation.</p><p><strong>Results: </strong>One hundred and fifty-six cases were enrolled, with 34 following the SP and 122 following the NP. In the univariate analysis, there were 15 explantations in the SP arm versus 8 for the NP arm due to infection (45.5% <i>vs.</i> 25%, P=0.09). The was no difference between the NP and the SP in multiparametric analysis [odds ratio (OR): 0.97; P=0.96]. No other risk factors were associated with increased risk of AUS removal.</p><p><strong>Conclusions: </strong>Our study showed no correlation between the two types of skin preparation and the risk of AUS removal or revision. Future studies are needed to highlight the legitimate risk factors.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 10","pages":"2168-2173"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31Epub Date: 2024-10-28DOI: 10.21037/tau-24-225
Xichen Su, Yonghe Huang, Xiaosen Wang, Li Cui
Background: Kidney renal papillary cell carcinoma (KIRP), kidney chromophobe (KICH), and kidney renal clear cell carcinoma (KIRC) are three most common subtypes of renal cell carcinomas (RCC), and its development is a multifaceted process that intricately involves the interplay of numerous genes. Despite recent advances in research on renal cell carcinoma, the prognosis of KIRC patients remains dismal. Therefore, there is an urgent need to explore new prognostic biomarkers and treatment strategies to help clinicians choose more effective treatment methods and accurately predict long-term efficacy. Our study aimed to systematically evaluate the gene expression profiles of three RCC subtypes, especially KIRC, and to identify survival-related biomarker.
Methods: In our present study, we systematically evaluate the genes expression profile difference among three subtypes of RCC, and identify the survival-related key genes signature based on GEPIA2. GeneMANIA was used to identify the functionality-related differentially expressed genes (DEGs). Furthermore, focusing on KIRC, we intersected functionality-related and survival-related DEGs based on two datasets.
Results: We ascertained five DEGs (ANK3, FREM2, KIF13B, MPP7 and SOX6) as key survival-related genes in KIRC. High levels of these five DEGs expressions were strongly associated with favorable prognosis, but not correlated to metastasis. Downregulation of these five DEGs expressions was closely associated with immunomodulators, chemokines, and infiltrating levels of different immune cells, which indicated that these five DEGs were key immune-related novel prognostic biomarkers for KIRC.
Conclusions: The five identified DEGs serve as potential novel prognostic biomarkers for KIRC. However, the crucial factors that lead to the downregulation and functional inactivation of these five key genes need to be explored in future studies.
{"title":"Molecular signature of immune-related new survival predictions for subtype of renal cell carcinomas.","authors":"Xichen Su, Yonghe Huang, Xiaosen Wang, Li Cui","doi":"10.21037/tau-24-225","DOIUrl":"10.21037/tau-24-225","url":null,"abstract":"<p><strong>Background: </strong>Kidney renal papillary cell carcinoma (KIRP), kidney chromophobe (KICH), and kidney renal clear cell carcinoma (KIRC) are three most common subtypes of renal cell carcinomas (RCC), and its development is a multifaceted process that intricately involves the interplay of numerous genes. Despite recent advances in research on renal cell carcinoma, the prognosis of KIRC patients remains dismal. Therefore, there is an urgent need to explore new prognostic biomarkers and treatment strategies to help clinicians choose more effective treatment methods and accurately predict long-term efficacy. Our study aimed to systematically evaluate the gene expression profiles of three RCC subtypes, especially KIRC, and to identify survival-related biomarker.</p><p><strong>Methods: </strong>In our present study, we systematically evaluate the genes expression profile difference among three subtypes of RCC, and identify the survival-related key genes signature based on GEPIA2. GeneMANIA was used to identify the functionality-related differentially expressed genes (DEGs). Furthermore, focusing on KIRC, we intersected functionality-related and survival-related DEGs based on two datasets.</p><p><strong>Results: </strong>We ascertained five DEGs (<i>ANK3, FREM2, KIF13B, MPP7</i> and <i>SOX6</i>) as key survival-related genes in KIRC. High levels of these five DEGs expressions were strongly associated with favorable prognosis, but not correlated to metastasis. Downregulation of these five DEGs expressions was closely associated with immunomodulators, chemokines, and infiltrating levels of different immune cells, which indicated that these five DEGs were key immune-related novel prognostic biomarkers for KIRC.</p><p><strong>Conclusions: </strong>The five identified DEGs serve as potential novel prognostic biomarkers for KIRC. However, the crucial factors that lead to the downregulation and functional inactivation of these five key genes need to be explored in future studies.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 10","pages":"2180-2193"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background and objective: Premature ejaculation (PE) and erectile dysfunction (ED) are two common sexual symptoms of male sexual dysfunction that can strongly affect men's mental health and quality of life, and they often coexist. This aim of this study was to explore the causes and relationships between PE and ED, with a focus on the progression of PE accompanied by high-frequency ED. A deeper understanding of the causes and treatments for PE combined with ED will help improve clinical diagnosis and treatment.
Methods: We conducted a literature review of the most relevant articles related to the outlined topic in the PubMed, Google Scholar, and Web of Science databases. We did not limit language, covering both English and non-English publications, and include Chinese and English papers published between January 1996 and March 2024.
Key content and findings: The incidence of PE and ED increases with age. Approximately one-third of patients who complain of ED suffer from PE. Similarly, in a large-scale survey in the Asia-Pacific region, more than 30% of patients with PE reported concurrent ED. Various research findings indicate a strong correlation between PE and ED. Some scholars speculate that there is a vicious cycle between PE and ED. Men who attempt to control ejaculation can reduce the level of arousal, leading to ED, whereas men who try to achieve an erection will attempt to increase the level of arousal, which can lead to PE. This cycle of mutual influence may lead to reciprocal aggravation and persistence of sexual dysfunction in both parties. Although some studies have explored the relationship between PE and ED, the specific determinants and underlying factors have not yet been clarified.
Conclusions: There is a close interrelationship between PE and ED, and a vicious cycle may exist between the two. This cycle of mutual influence may lead to the mutual aggravation and persistence of both sexual dysfunctions. However, the specific determining factors and potential factors underlying the correlation between the two have not been clearly identified and require further exploration.
背景和目的:早泄(PE)和勃起功能障碍(ED)是男性性功能障碍的两种常见性症状,会严重影响男性的心理健康和生活质量,而且这两种症状经常同时存在。本研究旨在探讨 PE 和 ED 之间的原因和关系,重点关注伴有高频 ED 的 PE 的进展情况。深入了解 PE 合并 ED 的原因和治疗方法将有助于改善临床诊断和治疗:我们对 PubMed、Google Scholar 和 Web of Science 数据库中与概述主题相关的最重要文章进行了文献综述。我们没有限制语言,涵盖了英文和非英文出版物,并收录了 1996 年 1 月至 2024 年 3 月间发表的中英文论文:PE 和 ED 的发病率随着年龄的增长而增加。约三分之一主诉 ED 的患者患有 PE。同样,在亚太地区的一项大规模调查中,超过 30% 的 PE 患者报告同时患有 ED。各种研究结果表明,PE 和 ED 之间存在密切联系。一些学者推测 PE 和 ED 之间存在恶性循环。试图控制射精的男性会降低性兴奋水平,从而导致 ED,而试图勃起的男性会试图提高性兴奋水平,从而导致 PE。这种相互影响的循环可能会导致双方性功能障碍的相互加重和持续存在。虽然一些研究探讨了 PE 和 ED 之间的关系,但具体的决定因素和潜在因素尚未明确:结论:PE 和 ED 之间存在密切的相互关系,两者之间可能存在恶性循环。这种相互影响的循环可能会导致这两种性功能障碍的相互加重和持续存在。然而,两者之间相关的具体决定因素和潜在因素尚未明确,需要进一步探讨。
{"title":"The correlation between premature ejaculation and a high incidence of erectile dysfunction and its research progress: a narrative review.","authors":"Shasha Min, Junyan Xu, Changjie Ren, Zhonglin Cai, Hongjun Li, Zhong Wang","doi":"10.21037/tau-24-204","DOIUrl":"10.21037/tau-24-204","url":null,"abstract":"<p><strong>Background and objective: </strong>Premature ejaculation (PE) and erectile dysfunction (ED) are two common sexual symptoms of male sexual dysfunction that can strongly affect men's mental health and quality of life, and they often coexist. This aim of this study was to explore the causes and relationships between PE and ED, with a focus on the progression of PE accompanied by high-frequency ED. A deeper understanding of the causes and treatments for PE combined with ED will help improve clinical diagnosis and treatment.</p><p><strong>Methods: </strong>We conducted a literature review of the most relevant articles related to the outlined topic in the PubMed, Google Scholar, and Web of Science databases. We did not limit language, covering both English and non-English publications, and include Chinese and English papers published between January 1996 and March 2024.</p><p><strong>Key content and findings: </strong>The incidence of PE and ED increases with age. Approximately one-third of patients who complain of ED suffer from PE. Similarly, in a large-scale survey in the Asia-Pacific region, more than 30% of patients with PE reported concurrent ED. Various research findings indicate a strong correlation between PE and ED. Some scholars speculate that there is a vicious cycle between PE and ED. Men who attempt to control ejaculation can reduce the level of arousal, leading to ED, whereas men who try to achieve an erection will attempt to increase the level of arousal, which can lead to PE. This cycle of mutual influence may lead to reciprocal aggravation and persistence of sexual dysfunction in both parties. Although some studies have explored the relationship between PE and ED, the specific determinants and underlying factors have not yet been clarified.</p><p><strong>Conclusions: </strong>There is a close interrelationship between PE and ED, and a vicious cycle may exist between the two. This cycle of mutual influence may lead to the mutual aggravation and persistence of both sexual dysfunctions. However, the specific determining factors and potential factors underlying the correlation between the two have not been clearly identified and require further exploration.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 10","pages":"2338-2350"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-31Epub Date: 2024-10-28DOI: 10.21037/tau-24-457
Shushang Chen, Mingfang Weng, Ronghui Lin, Junjie Wei, Lingfeng Zhu, Zhenghua Ju, Zhitao Lin, Bin Zhan, Ram A Pathak, Rashid K Sayyid, Rong Ge
Background: New medications are needed to improve outcomes of castration-resistant prostate cancer (CRPC). Psoralen has been reported to have anti-cancer properties for various tumors, but there are limited reports about psoralen treatment in prostate cancer (PCa). This study aimed to investigate the effect of psoralen on PC3 cells and to investigate potential underlying mechanisms of action.
Methods: The effect of psoralen on the proliferation and cell cycle progression of PC3 cells was determined using Cell Counting Kit-8 (CCK-8) test and flow cytometry, respectively. The differential gene profiles in PC3 cells treated with psoralen were determined with microarray analyses. The effect of psoralen on long non-coding RNA (lncRNA) ENST00000510619 expression in PC3 cells was detected by real-time quantitative polymerase chain reaction (RT-qPCR). The effect of psoralen and transfection of small interfering lnc-RNA (si-lncRNA) ENST00000510619 on cell viability, invasion ability, and migratory activity of PC3 cells were evaluated using the CCK-8 test, transwell assay, and wound healing, respectively.
Results: Psoralen significantly inhibited PC3 cells in a concentration- and time-dependent manner and caused G1 phase and G2/M phase cycle arrests. When screened with a fold change (FC) of ≥2 and a P value of <0.05, 1,716 lncRNAs and 1,160 messenger RNAs (mRNAs) were significantly up-regulated, whereas 3,269 lncRNAs and 3,263 mRNAs were significantly down-regulated in PC3 cells after psoralen treatment. Among the differentially down-regulated lncRNAs in which the signal of the probe showed significant differences compared to the background, lncRNA ENST00000510619 had the highest FC. The expression of lncRNA ENST00000510619 was shown to be down-regulated by psoralen in a concentration-dependent manner. CCK-8 assay, wound healing, and transwell assay showed that both psoralen and si-lncRNA ENST00000510619 transfection significantly inhibited the activity, invasion, and migration of PC3 cells (P<0.01 for all).
Conclusions: Psoralen was confirmed to inhibit proliferation and block the cell cycle in PC3 cells in this in vitro study. The molecular mechanism involves multiple differentially expressed lncRNAs and mRNAs and is related to the down-regulation of lncRNA ENST000000510619 expression. This study provides the experimental basis for the development of psoralen as a novel anti-CRPC drug and for the consideration of lncRNA ENST00000510619 as a potential clinical target for CRPC.
{"title":"The inhibition effect of psoralen on prostate cancer PC3 cells via down-regulation of long non-coding RNA ENST00000510619.","authors":"Shushang Chen, Mingfang Weng, Ronghui Lin, Junjie Wei, Lingfeng Zhu, Zhenghua Ju, Zhitao Lin, Bin Zhan, Ram A Pathak, Rashid K Sayyid, Rong Ge","doi":"10.21037/tau-24-457","DOIUrl":"10.21037/tau-24-457","url":null,"abstract":"<p><strong>Background: </strong>New medications are needed to improve outcomes of castration-resistant prostate cancer (CRPC). Psoralen has been reported to have anti-cancer properties for various tumors, but there are limited reports about psoralen treatment in prostate cancer (PCa). This study aimed to investigate the effect of psoralen on PC3 cells and to investigate potential underlying mechanisms of action.</p><p><strong>Methods: </strong>The effect of psoralen on the proliferation and cell cycle progression of PC3 cells was determined using Cell Counting Kit-8 (CCK-8) test and flow cytometry, respectively. The differential gene profiles in PC3 cells treated with psoralen were determined with microarray analyses. The effect of psoralen on long non-coding RNA (lncRNA) ENST00000510619 expression in PC3 cells was detected by real-time quantitative polymerase chain reaction (RT-qPCR). The effect of psoralen and transfection of small interfering lnc-RNA (si-lncRNA) ENST00000510619 on cell viability, invasion ability, and migratory activity of PC3 cells were evaluated using the CCK-8 test, transwell assay, and wound healing, respectively.</p><p><strong>Results: </strong>Psoralen significantly inhibited PC3 cells in a concentration- and time-dependent manner and caused G1 phase and G2/M phase cycle arrests. When screened with a fold change (FC) of ≥2 and a P value of <0.05, 1,716 lncRNAs and 1,160 messenger RNAs (mRNAs) were significantly up-regulated, whereas 3,269 lncRNAs and 3,263 mRNAs were significantly down-regulated in PC3 cells after psoralen treatment. Among the differentially down-regulated lncRNAs in which the signal of the probe showed significant differences compared to the background, lncRNA ENST00000510619 had the highest FC. The expression of lncRNA ENST00000510619 was shown to be down-regulated by psoralen in a concentration-dependent manner. CCK-8 assay, wound healing, and transwell assay showed that both psoralen and si-lncRNA ENST00000510619 transfection significantly inhibited the activity, invasion, and migration of PC3 cells (P<0.01 for all).</p><p><strong>Conclusions: </strong>Psoralen was confirmed to inhibit proliferation and block the cell cycle in PC3 cells in this <i>in vitro</i> study. The molecular mechanism involves multiple differentially expressed lncRNAs and mRNAs and is related to the down-regulation of lncRNA ENST000000510619 expression. This study provides the experimental basis for the development of psoralen as a novel anti-CRPC drug and for the consideration of lncRNA ENST00000510619 as a potential clinical target for CRPC.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 10","pages":"2294-2306"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}